SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Spruce Biosciences, Inc. backtest

10 trend-following strategies were compared on the full daily history of Spruce Biosciences, Inc.. 10 beat buy-and-hold CAGR; MACD ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is 볼린저 밴드 돌파 (CAGR 4.3%, MDD -30.2%).

Data 2020-10-09 ~ 2026-07-31daily bars 1,458 (5.8 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -73.5%, drawdown -100.0%).

Sharpe leader (same as main): MACD — CAGR 13.9%, MDD -88.0%, Sharpe 0.42, 55% exposure.

Return/drawdown alternative: 볼린저 밴드 돌파 — CAGR is 87.4%p higher than buy and hold, while drawdown improves by 12.0%p (CAGR 4.3%, MDD -30.2%, exposure 4%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
MACD
fast=6, slow=26, signal=16
13.9%-88.0%0.420.162.1x9855%
SMA 크로스오버
fast=6, slow=35
-46.8%-99.8%0.38-0.470.0x4431%
Donchian 채널 돌파
entryN=11, exitN=61
-54.0%-99.9%0.37-0.540.0x2657%
ROC 모멘텀
n=30, threshold=0
-51.2%-99.8%0.36-0.510.0x10830%
Parabolic SAR
step=0.055, maxStep=0.3
-9.9%-94.5%0.36-0.100.5x21241%
볼린저 밴드 돌파
n=12, k=3.2
4.3%-30.2%0.280.141.3x84%
ADX / DI 방향성
period=17, threshold=21
-51.5%-99.7%0.20-0.520.0x2221%
Supertrend
period=20, mult=1.9
-55.5%-99.8%0.09-0.560.0x3224%
Keltner 채널 돌파
emaPeriod=43, atrPeriod=25, mult=3.3
-16.2%-85.3%0.05-0.190.4x46%
EMA 크로스오버
fast=43, slow=125
-24.0%-87.2%-0.16-0.270.2x417%
Buy and hold-73.5%-100.0%0.31-0.740.0x1100%
0.0001 0.001 0.01 0.1 1x 2021 2022 2023 2024 2025 2026 MACDBuy and hold
MACD: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -25% -50% -75% -100% 2021 2022 2023 2024 2025 2026 Buy and holdMACD
MACD maximum drawdown -88.0% (2024-02-23 → 2025-05-22), recovered after 591 days.

Rules of the top strategy

Looks at the gap (MACD) between a short and long average crossing its own signal line.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next